Fig. 1.

Effects of Olaparib and Palbociclib as single-agents or in combination on the growth of ovarian cancer cell lines in vitro. (a) Dose-response curves of Olaparib or Palbociclib alone or combined in a panel of 12 ovarian cancer cell lines treated with varying concentrations of Olaparib and Palbociclib for 72 h. Combination index (CI) was calculated using CalcuSyn software with the Chou-Talalay equation. (b) EFO27, OVCAR8, A2780, SNU119, and COV362 ovarian cancer cell lines were treated with drugs for 7–10 days. Fresh medium with drugs was replaced every 3 days. At the end point, plates were fixed and stained with crystal violet stain. Representative images of plates are shown. Error bars represent standard deviations (S.D.) from the mean. EFO27, OVCAR8 and A2780: Olaparib (Ola), 2 μM; Palbociclib (Palb), 1 μM. SNU119 and COV362: Olaparib, 8 μM; Palbociclib, 4 μM. (c) Ovarian cancer cell lines were cultured in 3D matrigel and drug-treated for 10–15 days. Representative images of cells are shown. Quantification of scored structures (intact, semi-disintegrated and disintegrated) is shown. Scale bar, 200 μm. EFO27, OVCAR8, and A2780: Olaparib, 1 μM; Palbociclib, 0.5 μM. SNU119 and COV362: Olaparib, 4 μM; Palbociclib, 2 μM. (d) Ovarian cancer cell lines were drug-treated as indicated for 48 h. Flow cytometric analysis of Annexin V and propidium iodide (PI) stained cells was conducted to evaluate apoptosis. EFO27, OVCAR8 and A2780: Olaparib, 2 μM; Palbociclib, 1 μM. SNU119 and COV362: Olaparib, 8 μM; Palbociclib, 4 μM. Mean ± S.D. for three independent experiments are shown. *P < 0.05; **P < 0.01; ***P < 0.001 (Student's t-test). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)